Skip to main content
SpringerLink
Log in

Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism

  • Full Papers
  • Published:
Journal of Neural Transmission - Parkinson's Disease and Dementia Section

Summary

The influence of R(-) apomorphine, S(+) apomorphine and deopamine on the oxidation kinetics of two polyunsaturated fatty acids (PUFA) (cholesteryl linoleate (CL) and Trilinolein (TL) was investigated The oxidation was initiated by free radicals generated through thermal decomposition of 2,2'-Azobis(2-methy-propionitrile) (AMPN) in phosphate buffer (pH 7.4) thermostated at 50°C. The hydroperoxides formed were determined by iodine titration using a diode array spectrophotometer at 290 nm.

Both enantiomers of apomorphine as well as dopamine exerted an inhibitory effect. Tocopherol (α-tocopherol) and ascorbic acid were used as controls. The former inhibited while ascorbic acid facilitated the oxidation reaction.

These results are discussed i relation with the possible role of oxidative injury in parkinsonism and the usefulness of apomorphine in elevating “on-off” episodes. On this basis, the non-dopaminergic enantiomer of apomorphine (S(+)-isomer) is put foward to test the importance of its radical scavenging properties in parkinsonism which could eventually lead to a therapeutic alternative with less side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Adam D, Odunze IN (1991) Oxygen free radicals: their involvement in disease processes. Ann Clin Biochem 27: 161–169

    Google Scholar 

  • Barbaeau A (1974) The clinical physiology of side effects in long term L-dopa therapy. Adv Neurol 5: 347–365

    Google Scholar 

  • Ben-Shachar D, Eshe G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication in Parkinson's disease. Ann Neurol 32: s105-s110

    Google Scholar 

  • Biachi G, Landi M (1985) Determination of apomorphine in rat plasma and brain by highperfomance chromatography with electrochemical detection. J Chromatogr 338: 230–235

    Google Scholar 

  • Campbell A, Baldessarini R, Teicher M, Neumayer J (1985) σ(t)Apomorphins Selective inhibition of excitatory effects of dopamine injected to the limbic system of the rat. Neuropharmacol 24: 391–399

    Google Scholar 

  • Campbell A, Baldessarini R, Teicher M, Neumayer J (1986) Behavioral effects of apomorphine isomers in the rat: selective locomotor inhibitory effects of S(+)N-n-propylnorapomorphine. Psychopharmacol 88: 158–164

    Google Scholar 

  • Cebballos I, Lafon M, Javoy-Agid F, Hirsch E, Nicole A, Sinet PM, Agid Y (1990) Superoxide dismutase in parkinson's disease. Lancet 335: 1035–1036

    Google Scholar 

  • Cheknowa H, Costa LG, Woods JS, Castoldi A, Lund BO, Swanson PD (1992) Peripheral blood activities of monoamine oxidase B and superoxide dismutase in parkinson's disease. J Neural Transm [P-D Sect] 4: 283–290

    Google Scholar 

  • Chiueh CC, Miyake H, Peng MT (1993) Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 60: 251–258

    Google Scholar 

  • Cohen G (1990) Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm [Suppl] 32: 229–238

    Google Scholar 

  • Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989a) Basal lipid peroxidation in substantia nigra is increased in parkinson's disease. J Neurochem 52: 381–389

    Google Scholar 

  • Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989b) Increased nigral iron content and alteration in other metals ions occurring in brain in parkinson's disease. J Neurochem 52: 1830–1836

    Google Scholar 

  • Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Boodian CA (1989a) Selegline use to prevent progression of parkinson's disease. Experience in 22 de novo patients. Arch Neurol 46: 1275–1280

    Google Scholar 

  • Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA (1989b) Selegline as adjuvant in conventional levodopa therapy in parkinson's disease. Arch Neurol 46: 1280–1283

    Google Scholar 

  • Fischer PA, Baas H (1987) Therapeutic efficacy of (-)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm 25 [Suppl]: 137–147

    Google Scholar 

  • Frankel JP, Lees AJ, Kempester PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of parkinson's disease. J Neurol Neurosurg Psychiatry 53: 96–101

    Google Scholar 

  • Gancher ST, Woodward WR, Boucher B, Nutt JG (1989) Peripheral pharmacokinetic of apomorphine in humans. Ann Neurol 26: 232–238

    Google Scholar 

  • Graham GD, Tiffany SM, Bell WR, Gutknecht WF (1978) Autoxidation versus coval ent binding of ouinones as the mechanisms of toxicity of dopamine, 6-hydroxydop amie and elated compounds towards C1300 neuroblastoma cells in vivo. Mol Pharmacol 14: 644–653

    Google Scholar 

  • Halliwell B (1989) Oxidant and the central nervous system: some fundamental questions. Acta Neurol Scand 126: 23–33

    Google Scholar 

  • Hesagawa E, Takeshije K, Oishi T, Murai Y, Minakami S (1990) 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart mitochondrial particles. Biochem Biophys Res Commun 170: 1049–1055

    Google Scholar 

  • Hicks M, Gebicki JM (1979) A spectrophotometric method for determination of lipid hydroperoxides. Anal Biochem 99: 249–253

    Google Scholar 

  • Hofstee DJ, Neef C, van Laar T, Jansen ENH (1994) Pharmacokinetics of apomorphine in parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responces. Clin Neuropharmacol 17: 45–52

    Google Scholar 

  • Kebabian JW (1978) A sensitive enzymatic radioisotopic assay for apomorphine. J Neurochem 30: 114–144

    Google Scholar 

  • Lee T, Seeman P, Rajput A, Ferley IJ, Hornykiewicz O (1978) Receptor basis for dopaminegic supersensitivity in parkinson's disease. Nature 273: 5961

    Google Scholar 

  • Liu J, Mori A (1993) Monoamine metabolism provides antioxidant defence in the brain against oxidant and free radical induced damage. Arch Biochem Biophys 302: 118–127

    Google Scholar 

  • Mally J (1992) Some new aspects of the effects of deprenyl in parkinson's disease: retrospective study. J Neural Transm [P-D Sec] 4: 155–164

    Google Scholar 

  • Marsden CD, Parkes JD (1976) “On-off” effects in patients with parkinson's disease on chronic levodopa therapy. Lancet i: 292–296

    Google Scholar 

  • Montastruc JL, Rascol O, Gerald GM, Gualano V, Bagheri H (1991) Sublingual apomorphine in parkinson's diseae: a clinical and pharmacokinetic study. Clin Neuropharmacol 14: 432–437

    Google Scholar 

  • Niki E (1991) Action of ascorbic acid as a scvenger of active and stable oxygen radicals. Am J Clin Nutr 54: 1119S-1124S

    Google Scholar 

  • Obeso JA Grandas F, Vaamonde J, Luquin MR, Martinez-Lage JM (1987) Apomorphine infusion for motor fluctuations in parkinsons disease. Lancet i: 1376–1377

    Google Scholar 

  • Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early parkinsons's disease. N Engl J Med 328: 176–183

    Google Scholar 

  • Poewe W, Gerstenbrand F, Ransmayr G (1987) Experience with selegline in the treatment of parkinson's disease. J Neural Transm 25 [Suppl]: 147–150

    Google Scholar 

  • Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W (1988) Subcutaneous apomorphine in parkinsons disease. Lancet i: 1943

    Google Scholar 

  • Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, Cadet JL (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced neurotoxicity. Neurosci 12: 1658–1667

    Google Scholar 

  • Przedborski S, Levivier M, Paftopoulos C, Naini AB, Hildebrand J (1995) Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord 10: 28–36

    Google Scholar 

  • Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520

    Google Scholar 

  • Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD (1989) A selective increase in particulate superoxide activity in parkinsonian substanta nigra. J Neurochem 53: 692–697

    Google Scholar 

  • Sam E, Augustijns P, Verbeke N (1994) Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J Chromatogr B 658: 311–317

    Google Scholar 

  • Sam E, Jeanjean AP, Maloteaux JM, Verbeke N (1995) Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Met Pharmacokin 20: 27–33

    Google Scholar 

  • Seeman P, Van Tol HH (1993) Dopamine D-4 receptors bind inactive (+) aporphin es suggesting neuroleptic role. Sulpride not stereoselective. Eur J Pharmacol 233: 73–174

    Google Scholar 

  • Shaw KM, Lees AJ, Stern GM (1980) The impact of treatment with levedopa in parkinson's disease. Q j Med 49: 283–293

    Google Scholar 

  • Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MDH (1991) Selective increase in iron in substantia nigra zona compacta in parkinsonian brain. J Neurochem 56: 978–982

    Google Scholar 

  • Steiger JM, Quinn NP, Marsden CD (1992) The clinical use of apomorphine in parkinson's disease. J Neurol 239: 389–393

    Google Scholar 

  • Stibbe C, Lees A, Stern G (1987) Subcutaneous infusion of apomorphine and lisuride in the treatment of “on-off” fluctuations. Lancet ii: 871

    Google Scholar 

  • Stibbe CMH, Kempester PA, Lees AJ, Stern GM (1988) Subcutaneous apomorphine in parkinsonian “on-off” oscillations. Lancet i: 403–406

    Google Scholar 

  • Ubeda A (1993) Iron reducing and free radical scavenging properties of apomorphine and some related bezylisoquinolines. Free Radic Biol Med 15: 159–167

    Google Scholar 

  • Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D-4 receptor with high affinity for antipsychotic clozapine. Nature 350: 310

    Google Scholar 

  • Westerink BHC, Horn AS (1979) D neuroleptics prevent the penetration of dopamine agonists into the brain? Eur J Pharmacol 58: 39–48

    Google Scholar 

  • Yamamoto Y, Niki E, Kamiya Y, Shimasaki H (1984) Oxidation of phosphatidylcholine in homogenous solution and in water dispersion. Biochim Biophys Acta 795: 323–340

    Google Scholar 

Download references

Author information

Author notes

  1. N. Verbeke

    Present address: Labroatorium voor Galenische en Klinische Farmacie, Katholieke Universiteit Leuven, Gasthuisberg, Herestraat 49, B-300, Leuven, Belgium

Authors and Affiliations

  1. Labroatorium voor Galenische en Klinische Farmacie, Katholieke Universiteit Leuven, Gasthuisberg, Herestraat 49, B-300, Leuven, Belgium

    E. E. Sam

Authors
  1. E. E. Sam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Verbeke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sam, E.E., Verbeke, N. Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism. J Neural Transm Gen Sect 10, 115–127 (1995). https://doi.org/10.1007/BF02251227

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02251227

Key words

Search

Navigation